580 related articles for article (PubMed ID: 16338209)
1. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
Geylis V; Steinitz M
Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
[TBL] [Abstract][Full Text] [Related]
2. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.
Chauhan NB; Siegel GJ
J Neurosci Res; 2003 Oct; 74(1):142-7. PubMed ID: 13130516
[TBL] [Abstract][Full Text] [Related]
3. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
[TBL] [Abstract][Full Text] [Related]
4. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.
Lord A; Gumucio A; Englund H; Sehlin D; Sundquist VS; Söderberg L; Möller C; Gellerfors P; Lannfelt L; Pettersson FE; Nilsson LN
Neurobiol Dis; 2009 Dec; 36(3):425-34. PubMed ID: 19703562
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
Vasilevko V; Cribbs DH
Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Alzheimer's disease.
McGeer PL; McGeer E
Sci Aging Knowledge Environ; 2004 Jul; 2004(27):pe29. PubMed ID: 15243154
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
8. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease.
Morgan D; Gitter BD
Neurobiol Aging; 2004; 25(5):605-8. PubMed ID: 15172737
[TBL] [Abstract][Full Text] [Related]
9. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain.
Kim HD; Kong FK; Cao Y; Lewis TL; Kim H; Tang DC; Fukuchi K
Neurosci Lett; 2004 Nov; 370(2-3):218-23. PubMed ID: 15488326
[TBL] [Abstract][Full Text] [Related]
10. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide.
Lue LF; Walker DG
J Neurosci Res; 2002 Nov; 70(4):599-610. PubMed ID: 12404514
[TBL] [Abstract][Full Text] [Related]
11. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
Foster JK; Verdile G; Bates KA; Martins RN
Mol Psychiatry; 2009 Mar; 14(3):239-51. PubMed ID: 18957942
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-beta immunotherapies in mice and men.
Brendza RP; Holtzman DM
Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
[TBL] [Abstract][Full Text] [Related]
13. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.
Dodart JC; Bales KR; Gannon KS; Greene SJ; DeMattos RB; Mathis C; DeLong CA; Wu S; Wu X; Holtzman DM; Paul SM
Nat Neurosci; 2002 May; 5(5):452-7. PubMed ID: 11941374
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
Solomon B
Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
16. Current progress in beta-amyloid immunotherapy.
Schenk D; Hagen M; Seubert P
Curr Opin Immunol; 2004 Oct; 16(5):599-606. PubMed ID: 15342006
[TBL] [Abstract][Full Text] [Related]
17. Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice.
Sohn JH; So JO; Kim H; Nam EJ; Ha HJ; Kim YH; Mook-Jung I
Biochem Biophys Res Commun; 2007 Sep; 361(3):800-4. PubMed ID: 17678618
[TBL] [Abstract][Full Text] [Related]
18. The underestimated potential of the immune system in prevention of Alzheimer's disease pathology.
Mohajeri MH
Bioessays; 2007 Sep; 29(9):927-32. PubMed ID: 17688240
[TBL] [Abstract][Full Text] [Related]
19. Reduction of amyloid beta-peptide accumulation in Tg2576 transgenic mice by oral vaccination.
Ishii-Katsuno R; Nakajima A; Katsuno T; Nojima J; Futai E; Sasagawa N; Yoshida T; Watanabe Y; Ishiura S
Biochem Biophys Res Commun; 2010 Sep; 399(4):593-9. PubMed ID: 20682291
[TBL] [Abstract][Full Text] [Related]
20. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.
Weiner HL; Lemere CA; Maron R; Spooner ET; Grenfell TJ; Mori C; Issazadeh S; Hancock WW; Selkoe DJ
Ann Neurol; 2000 Oct; 48(4):567-79. PubMed ID: 11026440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
